Loading...

Yield10 Bioscience

DB:M6X2
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
M6X2
DB
$14M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The last earnings update was 21 days ago. More info.


Add to Portfolio Compare Print
  • Yield10 Bioscience has significant price volatility in the past 3 months.
M6X2 Share Price and Events
7 Day Returns
-4.8%
DB:M6X2
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-26.7%
DB:M6X2
-9.2%
DE Biotechs
-6.7%
DE Market
M6X2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Yield10 Bioscience (M6X2) -4.8% -9.4% 4.7% -26.7% - -97.5%
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • M6X2 underperformed the Biotechs industry which returned -9.2% over the past year.
  • M6X2 underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
M6X2
Industry
5yr Volatility vs Market

Value

 Is Yield10 Bioscience undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Yield10 Bioscience. This is due to cash flow or dividend data being unavailable. The share price is €0.997.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Yield10 Bioscience's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Yield10 Bioscience's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:M6X2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.92
NasdaqCM:YTEN Share Price ** NasdaqCM (2019-04-18) in USD $1.13
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Yield10 Bioscience.

DB:M6X2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:YTEN Share Price ÷ EPS (both in USD)

= 1.13 ÷ -0.92

-1.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Yield10 Bioscience is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Yield10 Bioscience is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Yield10 Bioscience's expected growth come at a high price?
Raw Data
DB:M6X2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.22x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
3.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Yield10 Bioscience, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Yield10 Bioscience's assets?
Raw Data
DB:M6X2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.57
NasdaqCM:YTEN Share Price * NasdaqCM (2019-04-18) in USD $1.13
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:M6X2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:YTEN Share Price ÷ Book Value per Share (both in USD)

= 1.13 ÷ 0.57

1.98x

* Primary Listing of Yield10 Bioscience.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Yield10 Bioscience is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Yield10 Bioscience's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Yield10 Bioscience has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Yield10 Bioscience expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
3.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Yield10 Bioscience expected to grow at an attractive rate?
  • Unable to compare Yield10 Bioscience's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Yield10 Bioscience's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Yield10 Bioscience's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:M6X2 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:M6X2 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 3.6%
DB:M6X2 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 95.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:M6X2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:M6X2 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 18 -8 2
2020-12-31 1 -9 2
2019-12-31 1 -9 2
DB:M6X2 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -9 -9
2018-09-30 1 -9 -11
2018-06-30 1 -9 -11
2018-03-31 1 -9 -11
2017-12-31 1 -8 -11
2017-09-30 1 -9 -8
2017-06-30 1 -11 -8
2017-03-31 1 -10 -8
2016-12-31 1 -14 -9
2016-09-30 1 -17 -11
2016-06-30 0 -17 -7
2016-03-31 1 -22 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Yield10 Bioscience is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Yield10 Bioscience's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:M6X2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Yield10 Bioscience Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:M6X2 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 -0.48 -0.48 -0.48 1.00
2020-12-31 -0.70 -0.69 -0.71 2.00
2019-12-31 -0.76 -0.67 -0.85 2.00
DB:M6X2 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.92
2018-09-30 -1.34
2018-06-30 -1.57
2018-03-31 -2.20
2017-12-31 -3.29
2017-09-30 -2.82
2017-06-30 -2.82
2017-03-31 -2.76
2016-12-31 -3.30
2016-09-30 -3.89
2016-06-30 -2.40
2016-03-31 -3.87

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Yield10 Bioscience will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Yield10 Bioscience's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Yield10 Bioscience has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Yield10 Bioscience performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Yield10 Bioscience's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Yield10 Bioscience does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Yield10 Bioscience's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Yield10 Bioscience's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Yield10 Bioscience's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Yield10 Bioscience Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:M6X2 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.56 -9.17 4.82
2018-09-30 0.53 -11.29 5.55
2018-06-30 0.67 -10.68 5.21
2018-03-31 0.68 -11.02 5.63
2017-12-31 0.94 -10.82 5.63
2017-09-30 1.18 -8.42 5.00
2017-06-30 1.43 -7.96 5.46
2017-03-31 1.33 -7.74 4.74
2016-12-31 1.16 -9.19 5.74
2016-09-30 0.92 -10.73 6.59
2016-06-30 0.31 -6.57 6.01
2016-03-31 0.86 -10.14 7.32
2015-12-31 1.35 -12.44 7.22
2015-09-30 2.11 -15.13 7.60
2015-06-30 2.88 -24.43 9.12
2015-03-31 2.83 -25.12 9.32
2014-12-31 2.80 -26.77 10.29
2014-09-30 1.97 -29.15 10.69
2014-06-30 1.44 -28.17 9.87
2014-03-31 2.45 -29.27 10.63
2013-12-31 3.78 -28.54 11.61
2013-09-30 5.15 -29.87 11.49
2013-06-30 5.72 -31.89 13.01
2013-03-31 4.94 -31.97 13.02
2012-12-31 2.50 3.96 13.25
2012-09-30 2.47 3.54 14.97
2012-06-30 2.27 1.73 15.69

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Yield10 Bioscience has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Yield10 Bioscience has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Yield10 Bioscience improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Yield10 Bioscience's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Yield10 Bioscience has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Yield10 Bioscience's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Yield10 Bioscience's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Yield10 Bioscience is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Yield10 Bioscience's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Yield10 Bioscience's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Yield10 Bioscience has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Yield10 Bioscience Company Filings, last reported 3 months ago.

DB:M6X2 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 5.71 0.00 5.77
2018-09-30 7.33 0.00 7.80
2018-06-30 9.58 0.00 9.65
2018-03-31 11.64 0.00 11.57
2017-12-31 13.50 0.00 14.49
2017-09-30 2.55 0.00 2.95
2017-06-30 2.24 0.00 3.01
2017-03-31 4.56 0.00 4.88
2016-12-31 6.37 0.00 7.31
2016-09-30 8.58 0.00 9.78
2016-06-30 4.14 0.00 3.71
2016-03-31 7.18 0.00 5.27
2015-12-31 13.03 0.00 12.27
2015-09-30 17.78 0.00 17.89
2015-06-30 22.96 0.00 22.71
2015-03-31 13.33 0.00 13.26
2014-12-31 18.80 0.00 20.05
2014-09-30 24.40 0.00 25.49
2014-06-30 6.86 0.00 5.53
2014-03-31 13.38 0.00 10.42
2013-12-31 20.40 0.00 19.21
2013-09-30 28.20 0.00 25.75
2013-06-30 34.60 0.00 31.68
2013-03-31 41.51 0.00 37.71
2012-12-31 47.34 0.00 43.77
2012-09-30 55.89 0.00 47.82
2012-06-30 62.67 0.00 48.16
  • Yield10 Bioscience has no debt.
  • Yield10 Bioscience has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Yield10 Bioscience has less than a year of cash runway based on current free cash flow.
  • Yield10 Bioscience has less than a year of cash runway if free cash flow continues to reduce at historical rates of -38.9% each year.
X
Financial health checks
We assess Yield10 Bioscience's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Yield10 Bioscience has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Yield10 Bioscience's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Yield10 Bioscience dividends.
If you bought €2,000 of Yield10 Bioscience shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Yield10 Bioscience's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Yield10 Bioscience's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:M6X2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:M6X2 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Yield10 Bioscience has not reported any payouts.
  • Unable to verify if Yield10 Bioscience's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Yield10 Bioscience's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Yield10 Bioscience has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Yield10 Bioscience's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Yield10 Bioscience afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Yield10 Bioscience has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Yield10 Bioscience's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Olly Peoples
COMPENSATION $381,812
AGE 60
TENURE AS CEO 2.5 years
CEO Bio

Dr. Oliver P. Peoples, also known as Olly, Ph.D., is a Co-founder of Metabolix Inc., and has been its Chief Executive Officer and President since October 17, 2016. Dr. Peoples served as its Chief Scientific Officer since January 2000. Dr. Peoples leads Metabolix, Inc. R&D organization which includes 14 Ph.D. scientists in molecular biology, genetics and plant biology. He served as Vice President for Research at Metabolix Inc. since January 2000. He served as Director of research and Vice President of Metabolix Inc. Prior to founding Metabolix, he served as a Research Scientist with the Department of Biology at the Massachusetts Institute of Technology where he emerged as a pioneer of the new field of metabolic pathway engineering and its applications in industrial biotechnology. He first identified the genetic pathways for PHA production in living organisms while at MIT and established the fundamental tools and methods for engineering bacteria and plants to produce PHA Natural Plastics. He has been a Director of Metabolix Inc., since June 1992. He has published numerous peer-reviewed academic papers and is an inventor of over 90 patents and patent applications worldwide. He received a Ph.D. in Molecular Biology from the University of Aberdeen, Scotland.

CEO Compensation
  • Olly's compensation has been consistent with company performance over the past year.
  • Olly's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Yield10 Bioscience management team in years:

2.5
Average Tenure
61
Average Age
  • The tenure for the Yield10 Bioscience management team is about average.
Management Team

Olly Peoples

TITLE
Co-Founder
COMPENSATION
$382K
AGE
60
TENURE
2.5 yrs

Tony Sinskey

TITLE
Co-Founder & Director
COMPENSATION
$55K
AGE
78

Kristi Snell

TITLE
VP of Research & Chief Science Officer
COMPENSATION
$340K
AGE
50
TENURE
2.5 yrs

Lynne Brum

TITLE
Vice President of Planning & Communications and Secretary
COMPENSATION
$318K
AGE
54
TENURE
2.5 yrs

Chuck Haaser

TITLE
VP of Finance
COMPENSATION
$252K
AGE
62
TENURE
2.5 yrs

Sarah Cecil

TITLE
General Counsel & Secretary
COMPENSATION
$510K
AGE
66
TENURE
12.4 yrs
Board of Directors Tenure

Average tenure and age of the Yield10 Bioscience board of directors in years:

5.3
Average Tenure
61
Average Age
  • The tenure for the Yield10 Bioscience board of directors is about average.
Board of Directors

Bob Van Nostrand

TITLE
Chairman of the Board
COMPENSATION
$80K
AGE
61
TENURE
5.5 yrs

Olly Peoples

TITLE
Co-Founder
COMPENSATION
$382K
AGE
60
TENURE
26.8 yrs

Edward Muller

TITLE
Chairman Emeritus
COMPENSATION
$84K
AGE
82

Tony Sinskey

TITLE
Co-Founder & Director
COMPENSATION
$55K
AGE
78
TENURE
26.8 yrs

Richard Hamilton

TITLE
Independent Director
COMPENSATION
$57K
AGE
56
TENURE
2.1 yrs

Peter Kellogg

TITLE
Independent Director
COMPENSATION
$45K
AGE
62
TENURE
12.1 yrs

Joe Shaulson

TITLE
Independent Director
COMPENSATION
$38K
AGE
52
TENURE
5.3 yrs

Danny Schnell

TITLE
Member of Scientific Advisory Board
TENURE
3.2 yrs

Michael Lassner

TITLE
Member of Scientific Advisory Board for Yield10 Bioscience
TENURE
3.2 yrs

Heike Sederoff

TITLE
Member of Scientific Advisory Board
TENURE
2.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Yield10 Bioscience's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Yield10 Bioscience has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for enhancing crop yield in the United States and Canada. The company, through its Smart Carbon Grid for Crops and T3 platforms, is involved in improving fundamental crop yield through enhanced photosynthetic carbon capture, as well as increased carbon utilization efficiency to increase seed yield. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was founded in 1992 and is headquartered in Woburn, Massachusetts.

Details
Name: Yield10 Bioscience, Inc.
M6X2
Exchange: DB
Founded: 1992
$12,755,486
12,468,219
Website: http://www.yield10bio.com
Address: Yield10 Bioscience, Inc.
19 Presidential Way,
Woburn,
Massachusetts, 01801,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM YTEN Common Stock Nasdaq Capital Market US USD 10. Nov 2006
DB M6X2 Common Stock Deutsche Boerse AG DE EUR 10. Nov 2006
Number of employees
Current staff
Staff numbers
22
Yield10 Bioscience employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 21:07
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/08
Last earnings filing: 2019/03/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.